Protecting Approved Care Act: Senate Bill Would Stop Medicare Advantage Plans From Reversing Approvals After Care
The Protecting Approved Care Act, introduced November 17, would ban Medicare Advantage plans from reversing approvals and downcoding after care.

Protecting Approved Care Act: Senate Bill Would Stop Medicare Advantage Plans From Reversing Approvals After Care
The Protecting Approved Care Act would stop Medicare Advantage plans from reversing a prior authorization approval after your patient gets care, reopening a payment decision without cause, or changing your billing code to pay less. Senators John Kennedy of Louisiana and Mark Kelly of Arizona introduced the bipartisan bill in the Senate on November 17, 2026. A House companion from Representatives Bob Onder of Missouri and Greg Landsman of Ohio has been in play since September. The bill is introduced, not passed. Nothing changes for your claims today. But the target is precise: the approval that means nothing once the visit is over.
Your practice knows this pattern. You get the authorization. You deliver the care. Then the plan denies for medical necessity, reopens the determination, or downcodes the claim and pays a lower level. You appeal with the same records you sent the first time. The bill would make the first approval stick, with narrow exceptions for fraud and good cause. Here is what the bill does, what the data says about how often approvals fail, and what to do with your Medicare Advantage claims while Congress decides.
Table of contents
- What the Protecting Approved Care Act does
- Why sponsors say approvals no longer hold
- The data: denials, appeals, and overturn rates
- What retroactive reversals cost your practice
- Who backs the bill
- What the bill leaves untouched
- What to do now, bill or no bill
- Frequently asked questions
Key takeaways
- The Protecting Approved Care Act, introduced November 17, 2026 by Senators Kennedy and Kelly, would ban Medicare Advantage plans from denying previously approved care on medical necessity grounds.
- Plans could reopen a coverage or payment decision only for good cause or reliable evidence of fraud. Downcoding to reduce payment without that showing would be barred.
- Protections extend to services that never required prior authorization. No-auth care gets treated as approved care.
- KFF analysis of 2025 insurer reports found Medicare Advantage plans denied 12% of standard prior authorization requests, and 67% of appealed denials were overturned.
- The AMA 2025 survey found 40 prior authorizations per physician per week taking 13 hours of physician and staff time. Reversals add a second round of that work on care already delivered.
See your practice reimbursement variance before rule changes impact cash flow.
We model your practice's historical code utilization against the updated conversion factors and regional GPCIs.
Calculate Practice Variance →What the Protecting Approved Care Act does
The Senate announcement lists four protections. Read them as four separate locks on the same door.
Lock 1: no medical-necessity reversal after approval. A Medicare Advantage plan could not deny previously approved care based on medical necessity. The plan judged necessity when it approved the request. The bill bars a second judgment after treatment.
Lock 2: no reopening without cause. A plan could not reopen a coverage or payment determination without good cause or reliable evidence of fraud. Plans keep the power to investigate suspected fraud and reopen for good cause. The bill raises the bar for reopening from plan discretion to a stated reason.
Lock 3: no downcoding to cut payment. A plan could not change the billing code assigned to a claim to reduce payment without good cause or reliable evidence of fraud. Downcoding, where a plan pays a lower-level code than the one you billed, is the quiet version of a denial. The claim pays, just for less, and many practices never notice the haircut.
Lock 4: no-auth services get the same protection. Services that do not require prior authorization get treated as if authorization was granted. A plan could not use the absence of an auth requirement as a back door to deny or downcode after the fact.
Senator Kennedy put the case in one line: insurance companies should not approve care and then refuse to pay after doctors do the work. Senator Kelly framed it as a patient promise: if a plan says it will cover a treatment, that should end the matter. Radiology Business covered the Senate introduction on November 19, noting that Medicare Advantage plans frequently require preapproval for imaging and interventional procedures, the exact services where a reversal after the scan or procedure leaves the practice holding the cost.
Why sponsors say approvals no longer hold
The bill responds to a specific complaint from practices: approvals reversed after care, coverage denied after delivery, repayment demanded months later. The Senate release says insurers increasingly approve prior authorizations, then reverse the decision, deny coverage, or demand repayment after patients receive care. Those reversals create financial uncertainty, add administrative work, and can push practices away from Medicare Advantage patients.
The House bill came first. Representatives Onder and Landsman introduced the Protecting Approved Care Act in the House in September 2026 as H.R. 10394. McKnights covered the House introduction as a direct shot at clawbacks: retroactive denial of care, scaling back approved coverage after treatment, and taking back payments for services that met prior authorization standards. The Senate bill carries the same structure into the upper chamber, which matters because a bill needs both chambers to move.
This is the second prior authorization fight in two weeks on this site. Our Aetna Medicare Advantage prior authorization denials lawsuit article covered Select Medical suing Aetna after 200 of 207 long-term acute care requests were refused. That case fights denials before care. This bill fights reversals after care. Together they describe the full arc: hard to get approved, and approval itself under pressure.
The data: denials, appeals, and overturn rates
Start with how often Medicare Advantage plans say no the first time. KFF collected the first year of prior authorization metrics that insurers had to post under the CMS 2024 rule, covering calendar year 2025. KFF found Medicare Advantage insurers denied 12% of standard prior authorization requests and 10% of expedited requests. Medicaid managed care denied 14% of standard requests. ACA Marketplace plans denied 18%.
The spread by insurer is wide. Among the 6 largest Medicare Advantage insurers KFF examined, standard denial rates ran from 5% at Elevance to 17% at UnitedHealth Group. Your denial risk depends on which plan your patient carries, not just what care you order.
Appeals tell the sharper story. In Medicare Advantage, 67% of appealed standard denials were overturned in 2025. Centene overturned more than 90% of appealed denials. Kaiser Permanente overturned 40%. A 67% overturn rate means two-thirds of the denials your practice fights were wrong on the plan's own second look, or fixed by records the plan already had. The older CMS data runs higher: KFF analysis of 2024 Medicare Advantage data found nearly 53 million prior authorization determinations, 7.7% denied, only 11.5% of denials appealed, and 80.7% of appeals overturned. Most denials never get appealed at all. The ones that do mostly win.
Now add the burden baseline. The AMA 2025 Prior Authorization Physician Survey, fielded among 1,000 practicing physicians in December 2025 and released May 13, 2026, found 40 prior authorizations per physician per week taking 13 hours of physician and staff time. Forty percent of physicians have staff who work only on prior authorization. Ninety-five percent say prior authorization delays access to necessary care. Ninety-four percent say it contributes to burnout. That is the cost of getting the first approval. A reversal after care bills you twice for the same decision.
The CMS rule already in force sets the clock. Under the CMS Interoperability and Prior Authorization Final Rule CMS-0057-F, impacted payers must decide urgent requests within 72 hours and standard requests within 7 calendar days from January 2026, give a specific denial reason, and run a Prior Authorization API from January 1, 2027. Faster first decisions help. They do not stop a plan from changing its mind later. That gap is what this bill aims at. Our Medicare AI prior authorization WISeR article covers the separate federal pilot that added prior auth to traditional Medicare, where targeted service use fell about 20% in 6 states.
What retroactive reversals cost your practice
Here is the number no coverage of this bill runs: what reopened and downcoded Medicare Advantage claims cost one small practice in rework alone, before lost revenue. Every input comes from a named source. The one assumption, the share of approved care that gets reopened or downcoded, is labelled.
Take a 3-physician practice. At the AMA average of 40 prior authorizations per physician per week, the practice files 120 requests a week, or 6,240 a year. Assume 8% of approved care later gets reopened, denied, or downcoded. That assumption sits below the 12% first-pass denial rate KFF measured, and it is labelled as an assumption because no public dataset counts reversals directly. Eight percent of 6,240 is 499 cases a year.
Price the rework. MGMA and HFMA data put basic denial rework at $25 per claim, with complex appeals running $118 to $181. A reopened determination with records, peer-to-peer time, and a written appeal is a complex case, not a basic resubmission. At $118 per case, 499 cases cost $58,882 a year in staff and clinician time. At $181, the cost is $90,319.
Price the haircut. A downcoded evaluation and management visit typically drops one level. At an assumed $40 difference per downcoded claim, 499 claims lose $19,960 a year even when every appeal succeeds on the medical-necessity question, because the code change itself cuts payment. Add rework at the low end and the total at risk is $78,842 a year for one 3-physician practice. That is the cost of approvals that do not hold.
Cost piece | Input | Yearly cost |
|---|---|---|
Prior authorizations filed | 120 per week, 6,240 per year (AMA average) | Baseline |
Cases reopened or downcoded | 8% assumption, 499 cases | Labelled assumption |
Rework at $118 per case | Complex appeal rate, MGMA/HFMA via AHIMA | $58,882 |
Downcode haircut at $40 per claim | One E/M level, assumed | $19,960 |
Total at risk | Rework plus haircut | $78,842 |
The manual transaction cost sits under all of this. A manual prior authorization costs your practice $12.88 per transaction against $5.38 fully electronic, per the CAQH Index 2024. Reopening a case means paying that transaction cost again, plus the phone and fax time the index prices at 24 minutes per request against 16 minutes through a portal. Our claim denials rising in 2026 article covers the Experian survey behind the denial trend, and the CMS CRUSH proposed rule article covers the fraud-check rule moving through CMS at the same time. CRUSH tightens enrollment and audits. This bill limits plan reversals. Your documentation has to satisfy both directions.
Who backs the bill
Medical groups lined up fast. The Medical Group Management Association endorsed the Senate bill on November 18. Anders Gilberg, MGMA senior vice president of government affairs, called prior authorization, denials, and downcoding three of the top administrative burdens for medical groups, and said the bill would give groups certainty that an approval means payment. MGMA had already written in support of the House bill on September 30, 2026.
The American Association of Orthopaedic Surgeons endorsed the House bill at introduction. AAOS said on September 15, 2026 that plans increasingly deny coverage retroactively, reduce payments, or recoup payments already sent, even when prior authorization was granted or never required. AAOS cited AMA data that 9 in 10 physicians say prior authorization increases burnout.
The Alliance of Specialty Medicine, representing more than 100,000 specialty physicians across 15 societies, wrote in support of H.R. 10394 on October 26, 2026. The Society of Interventional Radiology co-signed a support letter with 14 other trade groups in October. The Senate release carries statements from the American Podiatric Medical Association, the Healthcare Business Management Association, the American College of Allergy, Asthma and Immunology, and the American Academy of Family Physicians. Broad specialty support matters here because downcoding and reversals hit imaging, procedures, and office visits alike.
What the bill leaves untouched
Read the limits plainly. The bill covers Medicare Advantage plans. It does not cover commercial plans, Medicaid managed care, or traditional Medicare. Your commercial prior auth reversals stay governed by contract and state law.
The bill preserves plan power to investigate suspected fraud and reopen decisions for good cause. A plan with reliable evidence of fraud can still act. Practices with clean documentation gain protection. Practices with thin records gain less, because good cause will get argued over documentation gaps.
The bill does not reduce prior authorization volume. Plans can still require auth for the same services, deny at the same first-pass rates KFF measured, and run the same appeal process. Kennedy also cosponsored the Improving Seniors Timely Access to Care Act, which targets the front end with electronic prior authorization and transparency rules. This bill targets the back end: whether an approval survives contact with the claim.
And the bill is a bill. Introduction in both chambers with bipartisan sponsors and broad group support is a strong start. It is not law, has no effective date, and faces committee review in both chambers. Plan for the rules you have. Watch the bill for the rules you might get.
What to do now, bill or no bill
Four steps protect your Medicare Advantage revenue under current rules, and each one pays off if the bill passes.
Keep the approval with the claim. File the authorization number, the approved code set, and the approval letter in the chart where your biller can pull them in one step. A reversal appeal without the original approval in hand starts from zero. With it, your appeal letter writes itself: approved on this date, for these codes, care delivered as approved.
Track downcodes as denials. Most practices track denials and ignore downcodes because the claim paid something. Pull a monthly report of Medicare Advantage claims paid at a lower code level than billed. Price the gap. A $40 haircut on 40 claims a month is $19,200 a year, and it never appears on a denial report.
Appeal every reversal. KFF data says 67% of appealed Medicare Advantage denials were overturned in 2025, and 80.7% in 2024. The math favors fighting. A $118 complex appeal that recovers a $400 procedure pays for itself 3 times over. The cases you skip are the ones plans count on.
Write the note like the plan will read it twice. The first read gets the approval. The second read, after care, decides whether the approval holds. Document medical necessity in the visit note itself, with the finding that supports the code level you bill. Our medical billing services page covers the daily billing operation that keeps that paper trail clean, the revenue cycle management page shows the full-cycle team that works reversals within days, and a free audit pulls your last 90 days of Medicare Advantage claims and prices what reversals and downcodes already cost you.
Frequently asked questions
The Protecting Approved Care Act is a bipartisan bill introduced in the Senate on November 17, 2026 by Senators Kennedy and Kelly, with a House companion from Representatives Onder and Landsman. It would stop Medicare Advantage plans from reversing prior authorization approvals, reopening payment decisions without good cause, and downcoding claims after care is delivered.
No. The bill covers Medicare Advantage plans. Commercial plans, Medicaid managed care, and traditional Medicare stay under current contract terms and existing law. Prior authorization reversals by commercial payers would not change under this bill.
Yes. The bill preserves a plan ability to investigate suspected fraud and reopen decisions for good cause or reliable evidence of fraud. The change is the burden of showing cause before reversing an approval or cutting payment, rather than acting on plan discretion alone.
KFF analysis of insurer reports for 2025 found Medicare Advantage plans denied 12% of standard prior authorization requests and 10% of expedited requests. Rates by insurer ran from 5% to 17% for standard requests among the largest plans. In 2024, plans made nearly 53 million determinations and denied 7.7%.
KFF found 67% of appealed standard denials in Medicare Advantage were overturned in 2025. In 2024 CMS data, 80.7% of appealed denials were overturned, while only 11.5% of denials were appealed at all. Most denials go unchallenged, and most challenged denials win.
The bill has no effective date yet because it has only been introduced. It needs committee review and passage in both the House and Senate, then a presidential signature. No provision applies to your claims today. Track it as pending legislation, not as a current rule.
Protect your Medicare & fee schedule revenue.
Get a custom code-by-code reimbursement impact analysis for your practice. Measure your financial variance in 48 hours.
